Multiomics Machine Learning to Predict Neoadjuvant Chemotherapy Outcome and Relapse of Breast Cancer

2Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objective:The aim of this study was to investigate multiomics (MO) integration with stacked-ensemble learning for predicting neoadjuvant chemotherapy (NAC) response and recurrence risk in breast cancer (BC). Impact Statement: This study demonstrates that a stacked-ensemble learning model integrating clinicopathologic and magnetic resonance imaging (MRI)-based intratumoral heterogeneity biomarkers effectively predicts NAC response and postoperative recurrence risk in BC patients. These findings underscore MO and machine learning’s potential to optimize clinical decision-making. Introduction: Selecting BC patients who will benefit from NAC remains challenging. Methods: We retrospectively analyzed 124 BC patients receiving NAC (3 to 8 cycles) prior to mastectomy. Two radiomics signatures—RadSET and RadSITH—were derived from pre-NAC high-resolution dynamic MRI to track entire-tumor and intratumoral heterogeneous characteristics, respectively. These signatures were integrated with clinicopathologic indicators using stacked-ensemble learning algorithms to predict pathological complete response (pCR) and 3-year disease-free survival (DFS). Results: Among the 124 patients, the pCR rate was 26.6%. For pCR prediction, RadSITH and RadSET yielded areas under the curve (AUCs) of 0.798 and 0.770, respectively. The MO-integrated model, combining RadSITH, RadSET, clinical N stage, and molecular subtype, achieved a significantly higher AUC (0.917; 95% confidence interval [CI], 0.860 to 0.958; P < 0.05) than individual models. Postoperative recurrence occurred in 13.6% of patients. The elastic-net Cox model achieved a DFS concordance index of 0.78 (95% CI, 0.72 to 0.83) using pre-NAC variables (MO-predicted pCR, Response Evaluation Criteria in Solid Tumors response, RadSITH), and 0.81 (95% CI, 0.76 to 0.92) with post-NAC variables (pathologic grade, pCR status, pT stage, and pN stage). Conclusion: The MO integration with stacked-ensemble learning effectively predicts NAC response and recurrence risk in BC.

Cite

CITATION STYLE

APA

Wang, L., Zhang, X., Zhang, J., Liu, J., Chen, Y., Huang, W., & Xie, X. (2026). Multiomics Machine Learning to Predict Neoadjuvant Chemotherapy Outcome and Relapse of Breast Cancer. BME Frontiers, 7. https://doi.org/10.34133/BMEF.0212

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free